Background The aim of this study is to clarify the feasibility and effect of laparoscopic sleeve gastrectomy (LSG) on comorbidities, graft function and quality of life in patients who underwent renal transplantation (RT). Methods This is a retrospective review of five patients who underwent LSG after RT. Demographic data, anthropometric parameters, the effect on comorbidities, postoperative course, immunosuppressive medications, causes of RT, renal function, the survival of graft, and quality of life after SG in obese patients with a history of RT were assessed using BAROS–Moorhead–Ardelt survey Results From September 2015 to September 2019, 5 renal transplant patients underwent LSG; three female, and two male. Median body mass index (BMI) decreased from 42.17 kg/m2 (range 36–55) before surgery to 28.16 kg/m2 (range 25–42) after surgery. Improvement in blood pressure, triglyceride, and cholesterol levels was observed, and all cases were able to decrease their medications. Insulin was stopped and replaced with linagliptin in all diabetic patients. Graft function improved, and proteinuria level decreased in all cases. All patients reported to have an excellent quality of life. Conclusion LSG showed excellent outcomes in this high-risk group of patients regarding comorbidities, graft function and quality of life
BackgroundThe aim of this study is to clarify the feasibility and effect of laparoscopic sleeve gastrectomy (LSG) on comorbidities, graft function and quality of life in patients under went renal transplantation (RT) Methods This is a retrospective review of 5 patients who underwent laparoscopic sleeve gastrectomy (LSG) after kidney transplantation. Patients demographic data, anthropometric parameters, effect on comorbidities, postoperative course, immunosuppressive medications, cause of renal transplantation (RT), renal function, survival of graft, and post-sleeve gastrectomy quality of life in obese patients with history of renal transplantation (RT) were assessed using BAROS-Moorhead-Ardelt survey Results From September 2015 to September, 2019, 5 renal transplant patients underwent underwent laparoscopic sleeve gastrectomy (LSG); 60% were female and 40 were male with an average body mass index (BMI) before surgery of 41.28 ± 5.8 kg/m2 (range 36-55). Associated comorbidities: 100% of the patients had hypertension (HTN) and dyslipidemia (DSL), Whereas 3 patients (60%) had type 2 diabetes mellitus (T2D) and 1 patient had gout (20%). The average time between renal transplantation (RT) and laparoscopic sleeve gastrectomy (LSG) was 5.6 ± 5 years (range 3-9).Average operative duration was 61 ± 16.5 min (range 50-70), and there were neither postoperative morbidity nor mortality. At 17.9 ± 13.6 months (range 7-48) of follow-up period, body mass index (BMI) was 28.8 ± 6.3 kg/m2 (range 25-42). Regarding patients with hypertension (HTN) and dyslipidemia (DSL), improvement in blood pressure, triglyceride and cholesterol levels was observed and all cases were able to decrease their medications. Regarding diabetic patients, insulin was stopped in all patients and replaced with oral hypoglycemic medication only (linagliptin). Renal graft function and proteinuria level decreased in all cases (100%). All patients claimed to have excellent quality of life. ConclusionLSG showed excellent outcomes regarding weight reduction, improvement and resolution of
Background: The aim of this study is to clarify the feasibility and effect of laparoscopic sleeve gastrectomy (LSG) on comorbidities, graft function and quality of life in patients who underwent renal transplantation (RT) Methods: This is a retrospective review of 5 patients who underwent LSG after RT. Demographic data, anthropometric parameters, the effect on comorbidities, postoperative course, immunosuppressive medications, causes of RT, renal function, the survival of graft, and quality of life after SG in obese patients with a history of RT were assessed using BAROS–Moorhead–Ardelt survey Results From September 2015 to September 2019, 5 renal transplant patients underwent LSG; 60% were female, and 40 were male. Median body mass index (BMI) decreased from 42.17 kg/m2 (range 36–55) before surgery to 28.16 kg/m2 (range 25–42) after surgery. Improvement in blood pressure, triglyceride, and cholesterol levels was observed, and all cases were able to decrease their medications. Insulin was stopped and replaced with linagliptin in all diabetic patients. Graft function improved, and proteinuria level decreased in all cases (100%). All patients reported to have an excellent quality of life.Conclusion: LSG showed excellent outcomes in this high-risk group of patients regarding comorbidities, graft function and quality of life
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.